论文部分内容阅读
1.临床资料:治疗组男20例、女15例,年龄14～60岁,均符合全国第二届肾脏病变术会议诊断与分型标准。并随机选30例同期住院应用激素/免疫抑制剂的病人为对照组,对照组与治疗组在性别、年龄、病程等方面经统计学处理无显著性差异(P>0.05)。 2.治疗方法: ①治疗组:保肾康(四川济生制药厂分厂生产,每片50mg)每日600mg,分 3次口服,疗程 6～12月;强的松用法为;诱导量为0.6mg/kg/d,6周后缓慢减量,减至每日5 mg后维持用药半
1. Clinical data: The treatment group of 20 males and 15 females, aged 14 to 60 years old, are in line with the Second National Conference on Diagnosis and Classification of Nephropathy criteria. The patients in the same period were enrolled in the study. The control group and the treatment group had no significant difference (P> 0.05) in the aspects of gender, age and course of disease. 2. Treatment: ① Treatment group: Baoshenkang (Sichuan Jisheng Pharmaceutical Factory factory production, each tablet 50mg) daily 600mg, 3 times orally, course of treatment 6 to 12 months; prednisone usage is; induced amount of 0.6mg / kg / d, 6 weeks after the slow reduction, reduced to 5 mg daily after the maintenance of drug half